Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib vs Deucravacitinib in Moderate-to-Severe Plaque Psoriasis
NCT06973291Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Started Jul 2025; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06973291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973291.